{
    "name": "bempedoic acid",
    "comment": "Rx",
    "other_names": [
        "Nexletol"
    ],
    "classes": [
        "Lipid-Lowering Agents",
        "ACL Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/nexletol-bempedoic-acid-1000354",
    "pregnancy": {
        "common": [
            "Discontinue bempedoic acid when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus",
            "No available data regarding use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Note: Statins are contraindicated in pregnant women"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Treatment of hyperlipidemia is not generally necessary during pregnancy",
                    "Cholesterol and cholesterol derivatives are needed for normal fetal development"
                ]
            },
            {
                "type": "Animal studies",
                "description": [
                    "Bempedoic acid was not teratogenic in rats and rabbits when administered at doses resulting in exposures up to 11 and 12 times, respectively, the human exposures at the maximum clinical dose, based on AUC"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding drug presence in human or animal milk, effects on breastfed infants, or effects on milk production",
            "Since bempedoic acid decreases cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, these actions may cause harm to the breastfed infant",
            "Based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Hyperuricemia",
                    "description": [
                        "Inhibits renal tubular OAT2 and may increase blood uric acid levels",
                        "Elevated uric acid levels usually occurred within the first 4 weeks of treatment initiation and persisted throughout treatment; elevated blood uric acid may lead to gout"
                    ]
                },
                {
                    "type": "Tendon rupture",
                    "description": [
                        "Associated with increased risk of tendon rupture or injury",
                        "Tendon rupture occurred within weeks to months of initiating",
                        "May occur more frequently in patients aged â‰¥60 yr",
                        "Discontinue immediately if tendon rupture occurs",
                        "Consider discontinuing with joint pain, swelling, or inflammation"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Simvastatin or pravastatin",
                        "Coadministration increases simvastatin or pravastatin serum concentrations and may increase simvastatin/pravastatin-related myopathy",
                        "Avoid use with simvastatin doses >20 mg",
                        "Avoid use with pravastatin doses >40 mg",
                        "Atorvastatin and rosuvastatin: Elevations of 1.7-fold in AUC of atorvastatin, rosuvastatin, and/or their major metabolites were observed with bempedoic acid coadministration, suggesting a weak interaction; these elevations were generally within the individual statin exposures and do not affect dosing recommendations"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pravastatin",
            "description": {
                "common": "bempedoic acid increases levels of pravastatin by unknown mechanism. Modify Therapy/Monitor Closely. Avoid concomitant use with pravastatin dose 40 mg."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "simvastatin",
            "description": {
                "common": "bempedoic acid increases levels of simvastatin by unknown mechanism. Modify Therapy/Monitor Closely. Avoid concomitant use with simvastatin dose >20 mg."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infection",
            "percent": "4.5"
        },
        {
            "name": "Muscle spasms",
            "percent": "3.6"
        },
        {
            "name": "Hyperuricemia",
            "percent": "3.5"
        },
        {
            "name": "Back pain",
            "percent": "3.3"
        },
        {
            "name": "Abdominal pain or discomfort",
            "percent": "3.1"
        },
        {
            "name": "Bronchitis",
            "percent": "3"
        },
        {
            "name": "Pain in extremity",
            "percent": "3"
        },
        {
            "name": "Anemia",
            "percent": "2.8"
        },
        {
            "name": "Elevated liver enzymes",
            "percent": "2.1"
        },
        {
            "name": "Gout",
            "percent": "1.5"
        },
        {
            "name": "Benign prostatic hyperplasia",
            "percent": "1.3"
        },
        {
            "name": "Atrial fibrillation",
            "percent": "1.7"
        },
        {
            "name": "Tendon rupture",
            "percent": "0.5"
        }
    ]
}